different molecules under study for overnight at 4uC. The membranes were then washed three times for 15 min with TBS- T, and incubated with a 1:2000 dilution of horseradish peroxidase- coupled secondary antibodies (Santa Cruz Biotechnology) for 2 h at room temperature. Blots were again washed three times for 5 min each in TBS-T and developed by the ECLH detection system (Santa Cruz Biotechnology). Membranes were exposed to Fuji Medical X-Ray Film (Fuji Photo Film Co., Ltd, Karagawa, Japan). Statistical analysis Statistical analysis of the data was carried out by one way analysis of variance (ANOVA) followed by Scheffe’s post hoc test, References 1. Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27: 119–145. 2. Nakajima K, Kohsaka S (1998) Functional roles of microglia in the central nervous system. Hum Cell 11: 141–155. 3. Suzumura A, Takeuchi H, Zhang G, Kuno R, Mizuno T (2006) Roles of glia- derived cytokines on neuronal degeneration and regeneration. Ann N Y Acad Sci 1088: 219–229. 4. Fontana A, Gast H, Reith W, Recher M, Birchler T, Bassetti CL (2010) Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? Brain 133: 1300–1311. 5. Ankeny DP, Popovich PG (2009) Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. Neuroscience 158: 1112–1121. 6. Nam KN, Koketsu M, Lee EH (2008) 5-Chloroacetyl-2-amino-1,3-selenazoles attenuate microglial inflammatory responses through NF-kappaB inhibition. Eur J Pharmacol 589: 53–57. 7. Choi Y, Lee MK, Lim SY, Sung SH, Kim YC (2009) Inhibition of inducible NO synthase, cyclooxygenase-2 and interleukin-1beta by torilin is mediated by mitogen-activated protein kinases in microglial BV2 cells. Br J Phamrmacol 156: 933–940. 8. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, et al. (2009) Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer’s disease. Am J Pathol 175: 2121–2132. 9. Cao Q, Li P, Lu J, Dheen ST, Kaur C, Ling EA (2010) Nuclear factor-kappaB/ p65 responds to changes in the Notch signaling pathway in murine BV-2 cells and in amoeboid microglia in postnatal rats treated with the gamma-secretase complex blocker DAPT. J Neurosci Res 88: 2701–2714. 10. McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord 10: S3–S7. 11. Brown GC, Neher JJ (2010) Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 41: 242–247. 12. Ajmone-Cat MA, De Simone R, Nicolini A, Minghetti L (2003) Effects of phosphatidylserine on p38 mitogen activated protein kinase, cyclic AMP responding element binding protein and nuclear factor-kappaB activation in resting and activated microglial cells. J Neurochem 84: 413–416. 13. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124: 471–484. 14. Reiling JH, Sabatini DM (2006) Stress and mTORture signaling. Oncogene 25: 6373–6383. 15. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, et al. (2008) The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29: 565–577. 16. Thomson AW, Turnquist HR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9: 324–337. 17. Dello Russo C, Lisi L, Tringali G, Navarra P (2009) Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem Pharmacol 78: 1242–1251. 18. Lu DY, Liou HC, Tang CH, Fu WM (2006) Hypoxia-induced iNOS expression in microglia is regulated by the PI3-kinase/Akt/mTOR signaling pathway and activation of hypoxia inducible factor-1alpha. Biochem Pharmacol 72: 992–1000. 19. Erlich S, Alexandrovich A, Shohami E, Pinkas-Kramarski R (2007) Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis 26: 86–93. 20. Shakibaei M, Harikumar KB, Aggarwal BB (2009) Resveratrol addiction: to die or not to die. Mol Nutr Food Res 53: 115–128. 21. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493–506. 22. Shakibaei M, Csaki C, Nebrich S, Mobasheri A (2008) Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human Resveratrol Inhibit LPS-Induced Activation by mTOR using SPSS (SPSS Inc., Chicago, IL, USA). Summary data are shown as mean 6 SEM (standard error of mean) obtained from three independent experiments. Values of p,0.05 were considered significant. (#p,0.05, *p,0.05, np,0.05). Author Contributions Conceived and designed the experiments: DL CJX. Performed the experiments: LMZ YZ LS JZG YH. Analyzed the data: YZ WZ RS. Contributed reagents/materials/analysis tools: CJX LS WMW. Wrote the paper: DL LMZ LS. articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol 76: 1426–1439. 23. Imler TJ, Jr., Petro TM (2009) Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(2) IFN-gamma+ cells, and decreased macrophage IL-6 expression. Int Immunopharmacol 9: 134–143. 24. Marques FZ, Markus MA, Morris BJ (2009) Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol 41: 2125–2128. 25. Danz ED, Skramsted J, Henry N, Bennett JA, Keller RS (2009) Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 46: 1589–1597. 26. Olas B, Wachowicz B, Tomczak A, Erler J, Stochmal A, Oleszek W (2008) Comparative anti-platelet and antioxidant properties of polyphenol-rich extracts from: berries of Aronia melanocarpa, seeds of grape and bark of Yucca schidigera in vitro. Platelets 19: 70–77. 27. Lu X, Ma L, Ruan L, Kong Y, Mou H, et al. (2010) Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J Neuroinflammation 7: 46. 28. Anekonda TS (2006) Resveratrol–a boon for treating Alzheimer’s disease? Brain Res Rev 52: 316–326. 29. Klegeris A, McGeer EG, McGeer PL (2007) Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol 20: 351–357. 30. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37: 510–518. 31. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947. 32. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20: 5010–5018. 33. Lee KS, Kim SR, Park SJ, Lee HK, Park HS, et al. (2006) Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation. Mol Pharmacol 69: 1829–1839. 34. Tsoyi K, Kim WS, Kim YM, Kim HJ, Seo HG, et al. (2009) Upregulation of PTEN by CKD712, a synthetic tetrahydroisoquinoline alkaloid, selectively inhibits lipopolysaccharide-induced VCAM-1 but not ICAM-1 expression in human endothelial cells. Atherosclerosis 207: 412–419. 35. Liang X, Wu L, Wang Q, Hand T, Bilak M, et al. (2007) Function of COX-2 and prostaglandins in neurological disease. J Mol Neurosci 33: 94–99. 36. Hanisch UK (2002) Microglia as a source and target of cytokines. Glia 40: 140–155. 37. Nam KN, Park YM, Jung HJ, Lee JY, Min BD, et al. (2010) Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol 648: 110–116. 38. Szczepanik AM, Ringheim GE (2003) IL-10 and glucocorticoids inhibit Abeta(1–42)- and lipopolysaccharide-induced pro-inflammatory cytokine and chemokine induction in the central nervous system. J Alzheimers Dis 5: 105–117. 39. Vaillancourt F, Morquette B, Shi Q, Fahmi H, Lavigne P, et al. (2007) Differential regulation of cyclooxygenase-2 and inducible nitric oxide synthase by 4-hydroxynonenal in human osteoarthritic chondrocytes through ATF-2/ CREB-1 transactivation and concomitant inhibition of NF-kappaB signaling cascade. J Cell Biochem 100: 1217–1231. 40. Matsuda T, Omori K, Vuong T, Pascual M, Valiente L, et al. (2005) Inhibition of p38 pathway suppresses human islet production of pro-inflammatory cytokines and improves islet graft function. Am J Transplant 5: 484–493. 41. Hatziieremia S, Gray AI, Ferro VA, Paul A, Plevin R (2006) The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP kinase and NFkappaB signalling pathways in monocytes/macro- phages. Br J Pharmacol 149: 188–198. PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e32195